Statins may help prevent liver disease progression in compensated cirrhosis

There's currently no approved treatment to prevent hepatic decompensation — the critical turning point in cirrhosis — but a new large observational study is adding momentum to the case for statins. Presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting, the study analyzed over 18,000 adults with compensated cirrhosis and found that statin users had meaningfully lower rates of decompensation and death compared to non-users over a median follow-up of nearly 8 years.

Researchers believe statins may help through anti-inflammatory, antifibrotic, and portal pressure-reducing mechanisms. Still, the picture isn't entirely clear — prior randomized trials have shown unfavorable results, and the ongoing phase III SACRED trial of simvastatin is expected to provide more definitive answers.

By the Numbers:

• Hepatic decompensation: 18.2% (statin users) vs. 22.7% (non-users)
• Overall mortality: 14.6% vs. 21.2%
• Number needed to treat to prevent one decompensation episode: 25 at 5 years, 21 at 8 years
• Ascites, the most common first decompensation event, occurred in 12.7% of statin users vs. 17.1% of non-users

Why it matters: With no approved therapies to halt cirrhosis progression, these findings highlight a potentially accessible and affordable intervention. However, given the observational nature of the study and residual confounding risks, clinicians should await randomized trial data before broadly adopting statins for this indication.